Strs Ohio Sells 32,917 Shares of Bristol Myers Squibb Company $BMY

Strs Ohio trimmed its position in Bristol Myers Squibb Company (NYSE:BMY) by 6.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 499,705 shares of the biopharmaceutical company’s stock after selling 32,917 shares during the quarter. Strs Ohio’s holdings in Bristol Myers Squibb were worth $30,307,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in BMY. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. increased its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares in the last quarter. Bayban purchased a new stake in Bristol Myers Squibb in the 4th quarter worth $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BMY shares. HSBC upped their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Bank of America lowered their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Trading Down 0.1%

Shares of BMY stock opened at $58.05 on Friday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The stock’s 50-day moving average price is $56.90 and its 200-day moving average price is $57.49. The stock has a market capitalization of $118.54 billion, a price-to-earnings ratio of 16.31, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.